About each ml contains of ravulizumab
Long-acting complement C5 inhibitor
Used for
- Treats paroxysmal nocturnal hemoglobinuria (PNH).
- Treats atypical hemolytic uremic syndrome (aHUS).
- Treats generalized myasthenia gravis in eligible adults.
- Treats neuromyelitis optica spectrum disorder in eligible adults.
Usual adult dose
Intravenous infusion; dose depends on body weight and condition. After a loading dose, maintenance doses are given every 4 or 8 weeks.
Usual dose in children
For PNH and aHUS, intravenous dosing is weight-based; schedule depends on body weight and indication. Other uses are generally for adults.
Common side effects
- Headache
- Common cold or upper respiratory infections
- Diarrhea
- Nausea
Important warnings
- Can cause life-threatening meningococcal infection; vaccination is required, usually at least two weeks before treatment.
- Urgent antibiotics may be needed if treatment must start before vaccination is complete.
- Seek urgent care for fever, severe headache, stiff neck, rash, confusion, or light sensitivity.
- Increases susceptibility to certain other serious infections; vaccination does not eliminate this risk.
Pregnancy
Human pregnancy data are limited. Use only when potential benefit justifies potential risk; untreated disease can also harm pregnancy.
Breastfeeding
It is unknown whether ravulizumab passes into breast milk. Weigh treatment benefits against potential risks to the infant.
Interactions
- Other complement inhibitors may increase infection risk; concurrent use is generally avoided.
- Ravulizumab may interfere with certain laboratory tests, including tests for complement activity.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.